Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
On August 10, Harrow Inc. (NASDAQ:HROW) walked investors through a first half that fell short and a back half that now has to make up the difference.
Harrow Inc. (HROW)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Opaleye Management James A. Silverman | 2,400,000 | $101,928,000 | -16% | 9.23% |
| 2. | Private Capital Management Gregg J. Powers | 1,598,770 | $67,899,762 | +3% | 5.98% |
| 3. | Deep Track Capital David Kroin | 969,000 | $41,153,430 | 0.6% | |
| 4. | BAMCO Inc. Ron Baron | 809,350 | $34,373,094 | 0.05% | |
| 5. | Divisadero Street Capital William Zolezzi | 439,155 | $18,650,913 | 0.42% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.07 | 1,000 | $31,070.00 | 1,000 | 2026-05-18 | Filing | |
| $31.00 | 1,000 | $31,000.00 | 1,000 | 2026-05-18 | Filing | |
| $30.20 | 10,000 | $302,000.00 | 2,996,130 | 2026-05-14 | Filing | |
| $29.90 | 3,500 | $104,650.00 | 814,679 | 2026-05-14 | Filing | |
| $9.97 | 20,000 | $199,400.00 | 3,815,000 | 2024-04-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 11,250 | $450,000.00 | 0 | 2026-08-14 | Filing | |
| $39.67 | 4,263 | $169,122.16 | 59,428 | 2026-03-04 | Filing | |
| $39.67 | 134,000 | $5,316,061.40 | 3,622,000 | 2026-03-04 | Filing | |
| $39.15 | 1,309 | $51,250.49 | 63,691 | 2026-03-03 | Filing | |
| $39.15 | 59,000 | $2,309,991.60 | 3,756,000 | 2026-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,740,117 | $116,372,768 | 0% | |
| 2. | 1,417,212 | $60,188,994 | 0% | |
| 3. | 939,888 | $39,917,043 | 0% | |
| 4. | 905,560 | $38,466,487 | 0% | |
| 5. | 742,900 | $31,550,963 | 0% |
News See All
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million.
GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1
Grow Funds, an investment Advisor, released its Q1 2026 investor letter for “GROW Small Cap Equity Long/Short Fund”. A copy of the letter can be downloaded here.
Is Harrow, Inc. (HROW) A Good Stock To Buy Now?
Is HROW a good stock to buy? We came across a bullish thesis on Harrow, Inc. on TopSecretStocks’s Substack by Simon. In this article, we will summarize the bulls’ thesis on HROW.
Top 10 Small Cap Stocks With Huge Growth Potential
One of the key takeaways from Franklin Templeton’s Talking Markets podcast, published on May 14, was that for years, small-cap stocks were the market’s afterthought, overshadowed by the mega-cap names...
Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism
TheFly reported on May 14 that HROW had its price target reduced by B.Riley to $60 from $65 while a Buy rating was maintained.
8 Best Small Cap Pharma Stocks to Buy Right Now
Despite the concerns surrounding the Iran War, Haig Bathgate, CEO of Callanish Capital, stated on CNBC on May 7 that he was optimistic about global stocks.
Harrow Health, Inc. (NASDAQ:HROW) Q1 2026 Earnings Call Transcript
Operator: Good morning, and welcome to Harrow's First Quarter 2026 Earnings Conference Call. My name is Michelle, and I will be your operator for today's call.
Is Harrow, Inc. (HROW) A Good Stock To Buy Now?
Is HROW a good stock to buy? We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will summarize the bulls’ thesis on HROW.
Harrow Health, Inc. (NASDAQ:HROW) Q4 2025 Earnings Call Transcript
Operator: Welcome to the Harrow Health, Inc. fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode.
Hedge Fund Resource Center